Evidence map›Paper›PMID 40493241›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2025

Postoperative outcome and clinical management of tumor-induced osteomalacia: a single-center retrospective cohort study on 117 patients.

Ci Shan, Zhe Wei, Shanshan Li, Zeng Zhang, Hua Yue, Weijia Yu, Qingcheng Yang, Zhenlin Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ci ShanShanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Diseases, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
Zhe WeiShanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Diseases, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
Shanshan LiShanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Diseases, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
Zeng ZhangDepartment of Orthopedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
Hua YueShanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Diseases, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
Weijia YuDepartment of Osteoporosis and Bone Disease, Huadong Hospital, Fudan University, Shanghai, 200040, China.
Qingcheng YangDepartment of Orthopedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
Zhenlin ZhangShanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Diseases, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China. zhangzl@sjtu.edu.cn.ORCID http://orcid.org/0000-0002-4339-1617

Funding

National Key Research and Development Program of China 2018YFA0800801National Natural Science Foundation of China 81974123National Natural Science Foundation of China 82100941Shanghai Municipal Health Commission 20214Y0519
6 · The paper itself

Abstract

We reported a single-center retrospective cohort study on 117 patients of Tumor-induced osteomalacia (TIO) to summarize our experience with TIO over the past decade. The clinical characteristics, diagnosis, treatment and postoperative outcomes were analyzed. Together, our data demonstrate the characteristics and prognosis of TIO and unveil a possible TIO management process.

introductionTIO is a rare paraneoplastic syndrome that ultimately results in debilitating musculoskeletal deficits and regressive activity obstacles due to hypophosphatemia. The diagnosis and treatment of TIO are challenging owing to nonspecific symptoms, occult tumors and the lack of awareness. We aimed to summarize our experience with TIO over the past decade and to optimize its clinical management.

methodsA retrospective analysis was conducted of all patients with TIO admitted to our department and underwent surgical treatment at our hospital between 2012 and 2023. Clinical characteristics and postoperative outcomes were evaluated.

resultsA total of 117 patients with typical clinical characteristics were enrolled, manifesting diffuse bone pain, decreased serum phosphate and elevated serum intact fibroblast growth factor-23 (iFGF23). All the patients were managed using a stepwise pathway detailing diagnosis, identification of the causative tumors, operations and postoperative surveillance. The causative tumors were equally located in bone and soft tissues, and the main sites were the lower extremities and pelvis (63.2%). 117 cases were caused by phosphaturic mesenchymal tumors (PMTs), which were usually small and benign, with a median volume of 1.45cm

conclusionTIO patients were able to benefit from the management including early recognition and diagnosis of the disease, identification and complete removal of the causative tumors, followed by regular postoperative surveillance. Of particular concern were patients with bone-derived tumors, who had high non-remission and recurrence rates. CLINICAL

trial registrationThis study was registered with CHICTR.ORG.CN (ChiCTR2100042796).

Indexed as

Neoplasms, Connective TissueOsteomalaciaParaneoplastic SyndromesAdolescentAdultAgedFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansHypophosphatemiaMaleMiddle AgedRetrospective StudiesTreatment OutcomeYoung AdultFibroblast Growth Factor-23Fibroblast Growth FactorsClinical managementHypophosphatemiaRetrospective studyTumor-induced osteomalaciaTumors of soft tissue and bone

Identifiers

PMID40493241
PMCPMC12612011

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.